Impact of disparity between imaging and pathological tumor size on cancer-specific prognosis among patients with hepatocellular carcinoma
European Journal of Surgical Oncology · 2025-06 · 51 (6) · 109683
DOI: 10.1016/j.ejso.2025.109683 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Surgical Oncology, 2025-06. Verfasst von Miho Akabane und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The association between preoperative imaging and postoperative pathological tumor size disparity, and cancer-specific survival (CSS) among patients undergoing hepatectomy for hepatocellular carcinoma (HCC) remains unclear. We sought to evaluate this association and identify predictors of size disparity. METHOD: Patients undergoing curative-intent hepatectomy for HCC (2000-2023) were identified from an international, multi-institutional database. Size ratio was defined as the ratio of pathological to imaging tumor size. Patients with a size ratio of 0.5-1.5 were classified as "without size disparity," while patients outside this range were considered "with size disparity." Multivariable Cox regression was used to identify predictors of CSS, while logistic regression was utilized to determine factors associated with size disparity. For variables identified as significant in multivariable analyses, further evaluation including cutoff determination, were performed using receiver operating characteristic (ROC) analysis. RESULTS: Among 833 patients, median size ratio was 1.02, with a strong correlation between imaging and pathological tumor sizes (r = 0.87). Size disparity was present in 106 patients (12.7 %); in general, patients had smaller median imaging sizes (2.85 vs. 4.80 cm; p < 0.001) while size on pathology was noted to be larger(both 4.50 cm; p = 0.370). Patients with size disparity had worse 5-year CSS (60.1% vs. 79.0 %; p < 0.001). Multivariable Cox regression identified higher ALBI score (HR:2.56 [1.50-4.37]; p < 0.001), larger pathological tumor size (HR:1.09 [1.03-1.15]; p = 0.001), and size disparity (HR:2.53 [1.37-4.66]; p = 0.002) as independent predictors of CSS. Logistic regression demonstrated that cirrhosis (OR: 2.68 [1.43-5.02]; p = 0.002) and log alpha-fetoprotein (AFP) (OR:1.11 [1.01-1.22]; p = 0.030) were associated with an increased likelihood of size disparity. Cirrhosis and log AFP could be used to stratify patients relative to probability of a size disparity (low-risk:9.9 %, medium-risk:12.2 %, high-risk:17.7 %). The optimal AFP cutoff value was 3928 ng/mL for non-cirrhotic (AUC:0.90) versus 28.9 ng/mL for cirrhotic (AUC:0.74) patients. CONCLUSION: Tumor size disparity was associated with worse CSS among patients with HCC undergoing hepatectomy. Size disparity could be predicted preoperatively using cirrhosis status and AFP level, which may help identify high-risk patients who may benefit from more detailed imaging assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
- Department of Hepatobiliopancreatic Surgery, APHP, Beaujon Hospital, Clichy, France.
- Department of General Surgery, Cleveland Clinic Foundation, OH, USA.
- Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
- Department of Surgery, Keio University, Tokyo, Japan.
- Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada.
Zitieren
APA
Akabane, M., Kawashima, J., Altaf, A., Woldesenbet, S., Cauchy, F., Aucejo, F., Popescu, I., Kitago, M., Martel, G., Ratti, F., Aldrighetti, L., Poultsides, G. A., Imaoka, Y., Ruzzenente, A., Endo, I., Gleisner, A., Marques, H. P., Lam, V., Hugh, T., …, & Pawlik, T. M. (2025). Impact of disparity between imaging and pathological tumor size on cancer-specific prognosis among patients with hepatocellular carcinoma. European Journal of Surgical Oncology, 51(6), 109683. https://doi.org/10.1016/j.ejso.2025.109683
Vancouver
Akabane M, Kawashima J, Altaf A, Woldesenbet S, Cauchy F, Aucejo F, et al. Impact of disparity between imaging and pathological tumor size on cancer-specific prognosis among patients with hepatocellular carcinoma. European Journal of Surgical Oncology. 2025;51(6):109683. doi:10.1016/j.ejso.2025.109683
BibTeX
@article{Akabane2025,
author = {Akabane, Miho and Kawashima, Jun and Altaf, Abdullah and Woldesenbet, Selamawit and Cauchy, François and Aucejo, Federico and Popescu, Irinel and Kitago, Minoru and Martel, Guillaume and Ratti, Francesca and Aldrighetti, Luca and Poultsides, George A and Imaoka, Yuki and Ruzzenente, Andrea and Endo, Itaru and Gleisner, Ana and Marques, Hugo P and Lam, Vincent and Hugh, Tom and Bhimani, Nazim and Shen, Feng and Pawlik, Timothy M},
title = {Impact of disparity between imaging and pathological tumor size on cancer-specific prognosis among patients with hepatocellular carcinoma},
journal = {European Journal of Surgical Oncology},
year = {2025},
volume = {51},
number = {6},
pages = {109683},
doi = {10.1016/j.ejso.2025.109683}
}
EUVIMED